Altimmune, Inc. Chief Financial Officer Gregory L. Weaver filed a Form 4 on November 13, 2026, disclosing the vesting of 18,750 restricted stock units and the surrender of 5,672 shares to cover associated taxes, both transactions dated November 11, 2026.

Key Highlights

  • RSU vesting: 18,750 restricted stock units converted to common stock on November 11, 2026, at a price of $0 per unit.
  • Tax withholding: 5,672 shares were surrendered to Altimmune solely to cover taxes associated with the RSU vesting, at a price of $1.93 per share.
  • Remaining common stock: Following both transactions, Weaver directly held 63,005 shares of common stock.
  • Remaining RSUs: Weaver retains 37,500 derivative securities (RSUs) following the reported transaction.
  • Vesting schedule: The RSUs vest over four years, with 25% vesting on November 11, 2025, and the remainder in equal annual installments over the following three years, subject to continued service.
  • Issuer: Altimmune, Inc., traded on NASDAQ:ALT.

Weaver RSU Vesting and Tax-Withholding Transactions at Altimmune

According to the Form 4 filed with the SEC on November 13, 2026, Gregory L. Weaver, Chief Financial Officer of Altimmune, Inc. (NASDAQ:ALT), reported two non-derivative transactions and one derivative transaction, all dated November 11, 2026. The filing covers changes in Weaver's beneficial ownership of Altimmune common stock, par value $0.0001 per share.

The filing discloses that 18,750 restricted stock units were converted to common stock via transaction code "M" at a price of $0, reflecting a vesting event. As a result of this conversion, Weaver's direct holdings increased to 68,677 shares before the subsequent tax-withholding transaction. The filing notes that "each Restricted Stock Unit represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested." Immediately following, 5,672 shares were disposed of under transaction code "F," described in the filing as "shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs," at a price of $1.93 per share. After this disposition, Weaver's direct beneficial ownership of common stock stood at 63,005 shares.

In Table II, the filing shows that 18,750 RSUs were reduced from Weaver's derivative holdings via the same vesting event, leaving 37,500 RSUs remaining. The filing states the RSUs "become vested over four (4) years with 25% of the shares vesting on November 11, 2025, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date." All reported holdings are direct.

What Was Disclosed

Altimmune CFO Gregory L. Weaver disclosed the vesting of 18,750 RSUs and the surrender of 5,672 shares at $1.93 for tax withholding on November 11, 2026, leaving him with 63,005 shares of common stock and 37,500 remaining RSUs.